2-(p-Aminophenyl)-2-ethylglutarimide
aminoglutethimide
CAS: 125-84-8;55511-45-0
Molecular Formula: C13H16N2O2
2-(p-Aminophenyl)-2-ethylglutarimide - Names and Identifiers
| Name | aminoglutethimide |
| Synonyms | aminoglutethimide Aminoglutethimide TIMTEC-BB SBB000711 DL-Aminoglutethimide Aminoglutethimide(Ag) 2-(p-Aminophenyl)-2-ethylglutarimide 2-(4-aminophenyl)-2-ethylglutarimide 2-(p-aminophenyl)-2-ethyl-glutarimid 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione 2-(p-Aminophenyl)-2-ethylglutarimide2,6-piperidinedione, 3-(4-aminophenyl)-3-ethyl- |
| CAS | 125-84-8 55511-45-0 |
| EINECS | 204-756-4 |
| InChI | InChI=1/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17) |
2-(p-Aminophenyl)-2-ethylglutarimide - Physico-chemical Properties
| Molecular Formula | C13H16N2O2 |
| Molar Mass | 232.28 |
| Density | 1.1099 (rough estimate) |
| Melting Point | 152-154°C(lit.) |
| Boling Point | 374.44°C (rough estimate) |
| Flash Point | 230.4°C |
| Water Solubility | Soluble in water (2 mg/ml at 20°C), methanol (50 mg/ml), ethanol (7 mg/ml at 25°C), DMSO (20 mg/ml at 25°C), and chloroform. |
| Solubility | H2O: 0.2mg/mL, slightly soluble |
| Vapor Presure | 1.5E-08mmHg at 25°C |
| Appearance | neat |
| Color | white |
| Merck | 14,440 |
| pKa | 11.60±0.40(Predicted) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.6450 (estimate) |
| Use | For the treatment of breast cancer |
2-(p-Aminophenyl)-2-ethylglutarimide - Risk and Safety
| Hazard Symbols | Xi - Irritant |
| Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
| UN IDs | 3249 |
| WGK Germany | 3 |
| RTECS | MA4026950 |
| HS Code | 2925190100 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
2-(p-Aminophenyl)-2-ethylglutarimide - Upstream Downstream Industry
| Raw Materials | Acetic acid Acrylonitrile Acrylonitrile Methyl alcohol Methyl alcohol Potassium hydroxide Potassium hydroxide Phosphorus pentoxide Phosphorus pentoxide |
2-(p-Aminophenyl)-2-ethylglutarimide - Standard
Authoritative Data Verified Data
This product is 3-ethyl-3-(4-aminophenyl)-2, 6-piperidinedione. Calculated as dried product, the content of C13H16N202 shall not be less than 99.0%.
Last Update：2024-01-02 23:10:35
2-(p-Aminophenyl)-2-ethylglutarimide - Trait
Authoritative Data Verified Data
- This product is a white crystalline powder.
- This product is soluble in acetone, dissolved in methanol or chloroform, slightly soluble in ethanol, and slightly soluble in water.
melting point
The melting point of this product (General 0612) is 150~153°C.
absorption coefficient
take this product, precision weighing, and ethanol dissolution and quantitative dilution of about 10% per lml solution n according to UV-visible spectrophotometry (General 0401), the absorbance was measured at a wavelength of 242nm, and the absorption coefficient was 489 to 519.
Last Update：2022-01-01 15:37:29
2-(p-Aminophenyl)-2-ethylglutarimide - Differential diagnosis
Authoritative Data Verified Data
- take about 10mg of this product, add furfural solution (take 10 drops of furfural, add 10ml of glacial acetic acid, Shake) 3 drops, that is, red.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 417).
Last Update：2022-01-01 15:37:29
2-(p-Aminophenyl)-2-ethylglutarimide - Exam
Authoritative Data Verified Data
pH
Take 10mg of this product, add 0631 of methanol to dissolve, Add 10ml of water, shake, and determine according to law (General Rule 6.2), the pH value should be 7.3.
sulfate
take 0.25g of this product, add 1 ml of dilute hydrochloric acid, add appropriate amount of water to dissolve, check according to law (General rule 0802), compared with the control solution made of 0.02% of standard potassium sulfate solution, not more concentrated ().
Related substances
take this product, add acetate buffer (pH 5.0) (take 0.lmol/L acetic acid solution 120ml. 1 mol/L potassium hydroxide solution 100ml, diluted with water to 250ml, with dilute acetic acid or 0.1 mol/L potassium hydroxide solution after adjusting the pH value to 5.0, dilute with water to 1000mU, shake up)-methanol (50:50) dissolved and diluted to prepare a solution containing about 2mg per 1ml, as a test solution, 1ml was accurately weighed into a 50ml measuring flask, diluted to a scale with the above solvent, and shaken to obtain a control solution. According to the high performance liquid handle chromatography (General 0512) test, using eighteen alkyl silane bonded silica gel as filler, methanol-acetate buffer (pH5.0)(27:73) as mobile phase, the detection wavelength was 240nm. The LOLs of the test solution and the control solution were respectively injected into the liquid chromatograph, and the chromatogram was recorded to 4 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (2.0%).
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
Last Update：2022-01-01 15:37:30
2-(p-Aminophenyl)-2-ethylglutarimide - Content determination
Authoritative Data Verified Data
take this product about 0.2g, precision weighing, add glacial acetic acid 30ml dissolved, add crystal violet indicator liquid 1 drop, with perchloric acid titration solution (0.1 mol/L) titration to the solution is green, and the result of the titration is corrected with a blank test. Each 1 ml of perchloric acid titration solution (0.1 mol/L) corresponds to 23.23mg of C13H16N202.
Last Update：2022-01-01 15:37:31
2-(p-Aminophenyl)-2-ethylglutarimide - Category
Authoritative Data Verified Data
adrenocortical hormone inhibitors, antineoplastic agents.
Last Update：2022-01-01 15:37:31
2-(p-Aminophenyl)-2-ethylglutarimide - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 15:37:31
2-(p-Aminophenyl)-2-ethylglutarimide - Ambroxol tablets
Authoritative Data Verified Data
This product shall contain 93.0% ~ 107.0% of the labeled amount of amnurite (C13H16N202).
trait
This product is white tablet.
identification
- take an appropriate amount of the fine powder of this product (about 10 mg equivalent to amuramide), and show the same reaction according to the identification (1) Test under the item of amuramide.
- the sample solution under the content measurement item was taken and measured by ultraviolet-visible spectrophotometry (General 0401), and there was a maximum absorption at a wavelength of Nm.
examination
- dissolution the dissolution of this product was determined according to the dissolution and release determination method (General rule 0931, Method 1), with hydrochloric acid solution (7-100) as the dissolution medium, and the rotation speed was rpm, operate in accordance with the law, after 3 minutes, take about 10ml of the solution, filter, take the appropriate amount of the precise amount of filtrate, and quantitatively dilute with phosphate buffer (pH 7.4) to make a solution containing about 12.5ug per lm l, measure the absorbance at the wavelength of 237nm according to UV-Vis spectrophotometry (General rule 0401); Additionally, take about 12.5mg of the reference substance of aminoglutamide, weigh it accurately, and put it into a measuring flask, add hydrochloric acid solution (7-1000) to dissolve and dilute to the scale, Take 5ml into 50ml measuring flask, dilute to the scale with phosphate buffer (pH 7.4), shake well, and determine with the same method, the dissolution amount of each tablet was calculated. The limit is 70% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
Take 10 tablets of this product, precision weighing, fine grinding, precision weighing an appropriate amount (about 20mg equivalent to amulomide), put it in a 100ml measuring flask, and add an appropriate amount of ethanol, warm water bath to heat for 10 minutes to dissolve the aminoglutamide, let it cool, dilute to the scale with ethanol, shake well, filter, Take 5ml of continuous filtrate and put it in another 100ml measuring flask, dilute with ethanol to the scale, shake, as a test solution, according to UV-visible spectrophotometry (General 0401), at the wavelength of 242nm absorbance, calculated as the absorption coefficient of C13H16N202 is 504.
category
same as that of aminoglutamide.
specification
(l)0.125g (2 )0.25g
storage
light shielding, sealed storage.
Last Update：2022-01-01 15:37:32
2-(p-Aminophenyl)-2-ethylglutarimide - Reference Information
| pharmacological action | aminoglutamide, also known as amino-induced hypnotic, is an aromatase inhibitor, is glucometer (guided sleep) it can inhibit the production of estrogen by blocking aromatase and reduce the promoting effect of estrogen on breast cancer, thus inhibiting the growth of tumor. It can block the biosynthesis of androgen in two different parts of the adrenal cortex and gland tissue, and thus play a role in the removal of the drug. The conversion of cholesterol to pregnenolone in the adrenal gland is primarily prevented within the gland, thereby inhibiting the biosynthesis of autohormones in the adrenal cortex. It has a strong aromatase inhibitory effect in the surrounding tissues, preventing the conversion of androgens to estrogens. The major source of estrogen in postmenopausal women is the conversion of androstenedione, the precursor of androgens, by aromatization in fat, muscle and liver. This product inhibits the role of aromatization than the inhibition of adrenal cortical hormone synthesis greater than 10 times. The secretion of ACTH in the posterior pituitary can inhibit the synthesis of adrenal cortical hormone, so the use of this product at the same time with hydrocortisone, can block this effect of ACTH. The main treatment is advanced breast cancer (postmenopausal and estrogen receptor positive patients have better curative effect), ovarian cancer, prostate cancer and adrenocortical carcinoma. Also used for hypercortisolism (Cushing's syndrome) and adrenal tumors caused by the Cushing's syndrome. Figure 1 structural formula |
| pharmacokinetics | after oral administration, the product is rapidly and completely absorbed from the gastrointestinal tract, with a bioavailability of about 75%,1.5 hours blood drug concentration peak. Long-term high dose (daily 500mg) oral, blood peak concentration (Cmax) average of 9 μg/ml; Long-term low dose (Daily 125 ~ 250mg) oral, cmax was 0.5-1.5 μg/ml. Single drug, half-life of 12.5 hours, 2 weeks after the drug, half-life of 6~7 hours. The plasma protein binding rate of this product is 20% ~ 25%. It is mainly metabolized in the liver, and the main metabolite is N-acetylaminoglutamide. It is mainly excreted in the urine in the form of unchanged drugs (about 50%) and metabolites (25%), and rarely from the bile. |
| adverse reactions | 1. Nervous system: somnolence, dizziness, ataxia, nystagmus. 2. Digestive system: may appear loss of appetite, Nausea, Vomit, constipation, Diarrhea and hepatitis. 3. Skin: rash, itching, very rare exfoliative dermatitis, Stevens-Johnson syndrome, Lyell syndrome. 4. Respiratory system: hypersensitivity pneumonitis. 5. Blood system: neutropenia, thrombocytopenia, and even pancytopenia may occur, with occasional agranulocytosis. 6. Endocrine system: individual adrenal gland, hypothyroidism, female virilization, etc. |
| contraindication | 1. It is contraindicated in patients with porphyria. Disabled for children. 4. Patients with herpes zoster or other infections disabled. 5. Liver, renal insufficiency disabled. 6. Hypothyroidism is contraindicated. Shock period is contraindicated. It is contraindicated in diabetic patients with uncontrolled disease. Pregnant and lactating women disabled. |
| note | 1. Patients with surgery, trauma and other stress conditions and patients with hypotension should be used with caution. 2. During the medication should check the blood and blood electrolytes and blood, urine cortical hormone levels. Long-term treatment should always Monitor thyroid function and blood pressure. The pharmacological effects, pharmacokinetics, adverse reactions, and precautions of amikacin are compiled by Lijie. (2016-01-22) |
| drug interaction | 1. Combined with tamoxifen, the efficacy of both does not increase, but can increase the adverse reactions of this product, should not be used. This product can induce liver microsomal enzymes, promote the metabolism of warfarin, digitoxin, theophylline, reduce the effect of the latter. 3. Oral hypoglycemic drugs, corticosteroids and other drugs can accelerate the metabolism of this product. Severe sodium loss occurs when combined with benzfluorothiazide. |
| usage and dosage | oral: 250mg bid, 3~4 times a day after 2 weeks, daily dose should not exceed 1G. Hydrocortisone 40mg (10mg in the morning and 5 pm respectively, and 20mg before going to bed) should be used to prevent the pituitary from increasing feedback of adrenocortical hormones due to the decrease of cortisol produced by adrenal cortex. |
| production method | Brief description of production method: prepared from 2-P-chlorophenylbutyramide as raw material. |
| category | toxic substances |
| toxicity grade | poisoning |
| Acute toxicity | intraperitoneal-mouse LD50:625 mg/kg |
| flammability hazard characteristics | flammability; Toxic NOx smoke from combustion |
| storage and transportation characteristics | warehouse ventilation and low temperature drying |
| fire extinguishing agent | dry powder, foam, sand, carbon dioxide, water mist |
| NIST chemical information | information provided by: webbook.nist.gov (external link) |
| EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 21:04:16
Supplier List
View History
Raw Materials for 2-(p-Aminophenyl)-2-ethylglutarimide